Nina Wagner-Johnston
Overview
Explore the profile of Nina Wagner-Johnston including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
77
Citations
2557
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tabbara N, Zahurak M, Zahurak M, Sterling C, Sterling C, Trutzer I, et al.
Blood Adv
. 2024 Dec;
9(5):1202-1209.
PMID: 39693511
Patients with relapsed classic Hodgkin lymphomas (cHLs) receive salvage therapy with immune checkpoint inhibitors (ICIs) or chemotherapy (no-ICI). Patients responding to therapy often undergo consolidation with allogeneic blood or marrow...
2.
Komlodi-Pasztor E, Escarra-Senmarti M, Bazer D, Bhatnagar A, Perez Heydrich C, Messmer M, et al.
Front Immunol
. 2024 Sep;
15:1433442.
PMID: 39295862
The monoclonal antibody rituximab improves clinical outcome in the treatment of CD20-positive lymphomatous neoplasms, and it is an established drug for treatment of these cancers. Successful mRNA COVID-19 (SARS-CoV-2) vaccination...
3.
Wierda W, Brown J, Abramson J, Awan F, Bilgrami S, Bociek G, et al.
J Natl Compr Canc Netw
. 2024 Apr;
22(3):175-204.
PMID: 38626800
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are essentially different manifestations of the same disease that are similarly managed. A number of molecular and cytogenetic variables with prognostic...
4.
Batchelor T, Giri S, Ruppert A, Geyer S, Smith S, Mohile N, et al.
Blood Adv
. 2024 Apr;
8(12):3189-3199.
PMID: 38598710
Although it is evident that standard-dose whole-brain radiotherapy as consolidation is associated with significant neurotoxicity, the optimal consolidative strategy for primary central nervous system lymphoma (PCNSL) is not defined. We...
5.
Nichakawade T, Ge J, Mog B, Lee B, Pearlman A, Hwang M, et al.
Nature
. 2024 Mar;
628(8007):416-423.
PMID: 38538786
Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies. Adults with T cell leukaemias and lymphomas, collectively called T...
6.
Gerson J, Handorf E, Villa D, Gerrie A, Chapani P, Li S, et al.
Blood Adv
. 2023 Oct;
7(24):7393-7401.
PMID: 37874912
Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants...
7.
Desai S, Spinner M, Evens A, Sykorova A, Bachanova V, Goyal G, et al.
Blood Adv
. 2023 Sep;
7(23):7295-7303.
PMID: 37729621
In the pre-novel agent era, the median postprogression overall survival (PPS) of patients with classic Hodgkin lymphoma (cHL) who progress after autologous stem cell transplant (ASCT) was 2 to 3...
8.
Ly A, Sanber K, Tsai H, Ondo A, Mooney K, Shedeck A, et al.
Br J Haematol
. 2023 Aug;
203(4):688-692.
PMID: 37642134
No abstract available.
9.
Sanber K, Ly A, Ondo A, Mooney K, Baker J, Shedeck A, et al.
Am J Hematol
. 2023 Aug;
98(11):E301-E304.
PMID: 37539824
No abstract available.
10.
Webster J, Reed M, Tsai H, Ambinder A, Jain T, DeZern A, et al.
Transplant Cell Ther
. 2023 Jan;
29(3):182.e1-182.e8.
PMID: 36587740
Patients age ≥55 years with acute lymphoblastic leukemia (ALL) fare poorly with conventional chemotherapy, with a 5-year overall survival (OS) of ∼20%. Tyrosine kinase inhibitors and novel B cell-targeted therapies...